Thomas Broeer, managing director UK and Ireland for Aurobindo, has been at the helm of Aurobindo’s UK subsidiary, Milpharm Limited for almost two years and here discusses the UK market’s strengths, the potential impact of Brexit on the pharmaceutical industry and the pricing structures in place in the UK.
The UK was the first European affiliate to be set up by Indian-headquartered Aurobindo. Can you explain why Aurobindo chose the UK as the first EU market?
“The UK is an international bridge and provides access to Europe, America and Asia. Its Commonwealth history and global presence have substantial advantages. Besides its location and access, the UK is important in the financial world."
